Inotuzumab ozogamicin for MRD-positive B-ALL

Phase II study of inotuzumab ozogamicin in MRD+ B-ALLПодробнее

Blinatumomab vs inotuzumab ozogamicin for ALLПодробнее

The importance of blinatumomab and inotuzumab ozogamicin in treating ALLПодробнее

Inotuzumab ozogamicin for treating pediatric R/R ALLПодробнее

Inotuzumab ozogamicin for the treatment of elderly acute lymphoblastic leukemiaПодробнее

Inotuzumab ozogamicin & venetoclax in the treatment of B-ALL: findings from a Phase I trialПодробнее

Relapsed/Refractory ALL: Inotuzumab OzogamicinПодробнее

Phase II trial of inotuzumab ozogamicin to treat MRD+ B-ALLПодробнее

When to Use Inotuzumab Ozogamicin for Adult ALLПодробнее

Inotuzumab as a potential treatment for elderly patients with ALLПодробнее

MRD-Positive ALL: Personal Approaches to TreatmentПодробнее

Dose-adjusted EPOCH plus inotuzumab ozogamicin for B-ALLПодробнее

Dr. Brammer on Data With Inotuzumab Ozogamicin in ALLПодробнее

What is the role of inotuzumab ozogamicin in ALLПодробнее

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of ...Подробнее

What’s next for inotuzumab ozogamicin in ALL?Подробнее

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALLПодробнее

Emerging novel approaches for ALL: inotuzumab ozogamicinПодробнее

Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALLПодробнее